Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis Zarif K. Jabbar-Lopez, Zenas Z.N. Yiu,

Slides:

Advertisements

Similar presentations

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Advertisements

From: Conceptual and Technical Challenges in Network Meta-analysis

Difficult-to-Treat Psoriasis: Gaining Control of Palmoplantar and Nail Psoriasis.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta- Analysis of Randomized Trials Sripal Bangalore, MD, MHA, Bora Toklu,

Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study Ingrid Snekvik, Catherine H. Smith,

TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study Robert Bissonnette, François Harel,

Perspectives in Psoriasis: Assessing Treatment Efficacy—Which Measures, What Do They Tell Us?

Efficacy of perineural vs systemic dexamethasone to prolong analgesia after peripheral nerve block: a systematic review and meta-analysis M. Baeriswyl,

Paravertebral block in paediatric abdominal surgery'a systematic review and meta- analysis of randomized trials E.A. Page, K.L. Taylor British Journal.

Courtney J. Warner, MD, MS, Spencer W. Greaves, MPH, Robin J

Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis Zenas Z.N. Yiu, Lesley S. Exton, Zarif.

Treatment of Nightmares With Prazosin: A Systematic Review

Efficacy of simvastatin in plaque psoriasis: A pilot study

Type I pityriasis rubra pilaris treated with tumor necrosis factor inhibitors, ustekinumab, or secukinumab: A review Nolan J. Maloney, BS, Lisa D. Hisaw,

Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials Kenneth R. McQuaid, MD, Loren.

Establishing an Academic–Industrial Stratified Medicine Consortium: Psoriasis Stratification to Optimize Relevant Therapy Christopher E.M. Griffiths,

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Development and Validation of an Algorithm to Accurately Identify Atopic Eczema Patients in Primary Care Electronic Health Records from the UK Katrina.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists.

Non-opioid analgesics in adults after major surgery: systematic review with network meta-analysis of randomized trials V Martinez, H Beloeil, E Marret,

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Amy S. Paller, MD, Elaine C. Siegfried, MD, David M

Research Techniques Made Simple: Understanding Network Meta-Analysis

Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta- Analysis of Randomized Trials Sripal Bangalore, MD, MHA, Bora Toklu,

Emily Edson-Heredia, Kimberly L. Sterling, Carlos I

TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study Robert Bissonnette, François Harel,

Partik Singh, BA, Jonathan I. Silverberg, MD, MPH, PhD

Clinical Snippets Journal of Investigative Dermatology

Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period

Aaron M. Drucker, Patrick Fleming, An-Wen Chan

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis Kristian Reich,

Re: Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis Zarif K. Jabbar-Lopez, Zenas Z.N.

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis Kenneth B. Gordon, Richard G. Langley,

Drugs for Treating Opioid-Induced Constipation: A Mixed Treatment Comparison Network Meta-analysis of Randomized Controlled Clinical Trials Kannan Sridharan,

Amy C. Foulkes, David S. Watson, Daniel F. Carr, John G

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Luigi Naldi Journal of Investigative Dermatology

A Randomized-Controlled Trial of Oral Low-Dose Isotretinoin for Difficult-To-Treat Papulopustular Rosacea Emilie Sbidian, Éric Vicaut, Henri Chidiack,

Diet or Exercise Interventions vs Combined Behavioral Weight Management Programs: A Systematic Review and Meta-Analysis of Direct Comparisons David J.

The relative efficacy of topical non-steroidal anti-inflammatory drugs and capsaicin in osteoarthritis: a network meta-analysis of randomised controlled.

Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis Alexander Nast, Anja Jacobs,

Databases for Clinical Research

Research Techniques Made Simple: Network Meta-Analysis

EXPERT INSIGHTS: IL-17 INHIBITION IN PSORIASIS CARE

Shrinking the Psoriasis Assessment Gap: Early Gene-Expression Profiling Accurately Predicts Response to Long-Term Treatment Joel Correa da Rosa, Jaehwan.

Comment on “Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis” Kristian Reich, Craig Leonardi,

Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis Eleanor J. Samarasekera, Julie M. Neilson, Richard.

Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients’ Medication Beliefs and Habit Strength Rachael J. Thorneloe,

Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective Bruno Salgado Riveros,

Efficacy of low frequency pulsed subsensory threshold electrical stimulation vs placebo on pain and physical function in people with knee osteoarthritis:

S. Seshadri, S.K. Sunkara, Y. Khalaf, T. El-Toukhy, H. Hamoda

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association.

Efficacy and adverse effects of ketamine as an additive for paediatric caudal anaesthesia: a quantitative systematic review of randomized controlled trials†

Efficacy of Systemic Treatments of Psoriasis on Pruritus: A Systemic Literature Review and Meta-Analysis Chloé Théréné, Emilie Brenaut, Thomas Barnetche,

Sigrun A.J. Schmidt, Serigne Lo, Loes M. Hollestein

Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study Nina Wilkinson,

HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program Katherine Li, C. Chris Huang, Bruce Randazzo,

Journal of Investigative Dermatology

Journal of Investigative Dermatology

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Journal of Investigative Dermatology

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial Boni E. Elewski, MD, Martin.

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks Esther von Stebut, Kristian.

Alan Menter, MD, Stephen K

Program. The Impact of Treatment Success and Failure in Psoriasis: Implications for Clinical Practice.

Efficacy and safety of antiscabietic agents: A systematic review and network meta- analysis of randomized controlled trials Kunlawat Thadanipon, MD, Thunyarat.

Presentation transcript:

Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis Zarif K. Jabbar-Lopez, Zenas Z.N. Yiu, Victoria Ward, Lesley S. Exton, M. Firouz Mohd Mustapa, Eleanor Samarasekera, A. David Burden, Ruth Murphy, Caroline M. Owen, Richard Parslew, Vanessa Venning, Richard B. Warren, Catherine H. Smith Journal of Investigative Dermatology Volume 137, Issue 8, Pages 1646-1654 (August 2017) DOI: 10.1016/j.jid.2017.04.009 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Flow diagram showing the identification of literature in the PRISMA format. RCT, randomized controlled trial. Journal of Investigative Dermatology 2017 137, 1646-1654DOI: (10.1016/j.jid.2017.04.009) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Network maps for the main outcomes considered in the review. (a) Clear/nearly clear (minimal residual activity/PASI > 90/0 or 1 on PGA). (b) Mean change in the dermatology life quality index. (c) Withdrawal due to adverse events, all at 12 to 16 weeks. Nodes and edges are weighted according to number of studies including that treatment or comparison. ADA, adalimumab; ETA, etanercept; INF, infliximab; IXE, ixekizumab; MTX, methotrexate; PASI, psoriasis area and severity index; PBO, placebo; PGA, physician’s global assessment; SEC, secukinumab; UST, ustekinumab. Journal of Investigative Dermatology 2017 137, 1646-1654DOI: (10.1016/j.jid.2017.04.009) Copyright © 2017 The Authors Terms and Conditions

Figure 3 Plot of joint rankings based on hierarchical clustering of the surface under the cumulative ranking curve (SUCRA) estimates. Combined estimates of efficacy (clear/nearly clear—minimal residual activity/PASI > 90/0 or 1 on PGA) and tolerability (withdrawal due to adverse events) at 12 to 16 weeks. ADA, adalimumab; ETA, etanercept; INF, infliximab; IXE, ixekizumab; MTX, methotrexate; PASI, psoriasis area and severity index; PBO, placebo; PGA, physician’s global assessment; SEC, secukinumab; UST, ustekinumab. Journal of Investigative Dermatology 2017 137, 1646-1654DOI: (10.1016/j.jid.2017.04.009) Copyright © 2017 The Authors Terms and Conditions